Cover Image
市場調查報告書

抗癌激酶抑制劑:全球市場及開發平台分析

Global Cancer Kinase Inhibitors Market & Pipeline Insight

出版商 KuicK Research 商品編碼 316010
出版日期 內容資訊 英文 1500 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗癌激酶抑制劑:全球市場及開發平台分析 Global Cancer Kinase Inhibitors Market & Pipeline Insight
出版日期: 2014年10月01日 內容資訊: 英文 1500 Pages
簡介

關於激酶抑制劑的作用在過去二十年的持續研究下,在癌症治療的應用上也徐徐擴大。這些藥劑在市場上有日益增多的可用性,讓製藥業者可開發更多新的組合方式。

本報告提供抗癌激酶抑制劑的市場與開發平台趨勢相關調查,提供您激酶抑制劑種類與概要,作用機制,激酶抑制抗癌藥的需求,激酶抑制劑的市場規模的變化與預測,彙整地區的明細,開發平台狀況,主要經營者簡介等資料。

第1章 激酶抑制劑:簡介

  • 癌症增生抑制劑
  • 癌症增生抑制劑的各種類型
  • 蛋白酪氨酸激酶抑制劑

第2章 激酶抑制劑的分類

  • I型激酶抑制劑
  • II型激酶抑制劑
  • III型激酶抑制劑
  • IV型激酶抑制劑或Substrate Directed Inhibitors
  • 共價抑製劑

第3章 激酶抑制劑的作用機制

  • 蛋白酪氨酸激酶的生物化學作用機制
  • 蛋白酪氨酸激酶的致癌作用
    • 突然變異的致癌
    • BCR-ABL和人類白血病
    • TEL-ABL和人類白血病
    • 自體分泌(autocrine)·副分泌(paracrine)迴路
    • 自體分泌(autocrine)·副分泌(paracrine)迴路的EGFR
    • 自體分泌(autocrine)·副分泌(paracrine)迴路的PDGFR
    • 自體分泌(autocrine)迴路的胰島素先生成長因素受體
  • 抗癌藥的標的的蛋白酪氨酸激酶

第4章 激酶抑制抗癌藥的需求

第5章 激酶抑制抗癌藥的市場概要

  • 目前市場方案
  • 抗癌激酶抑制劑的開發平台概要

第6章 激酶抑制抗癌藥的市場動態

  • 變成有利的參數
  • 阻礙成長要素

第7章 激酶抑制抗癌藥市場未來展望

第8章 激酶抑制抗癌藥的開發平台:相·適應症·企業·各國

  • phase:不明
  • phase:研究
  • phase:前臨床
  • phase:臨床
  • 第一階段
  • 第一階段/II
  • 第二階段
  • 第II/IIIphase
  • 第三階段
  • 核准前
  • 已通過核准

第9章 已上市激酶抑制抗癌藥:適應症·企業·各國

第10章 延期·中止的開發平台藥物

  • 無進展報告
  • 中止
  • 延期

第11章 競爭環境

  • Amgen
  • AstraZeneca
  • AVEO Pharmaceuticals
  • Bayer HealthCare Pharmaceuticals
  • Boehringer Ingelheim
  • Deciphera Pharmaceuticals
  • Genentech
  • GlaxoSmithKline
  • Incyte Corporation
  • Novartis
  • Pfizer
  • 武田藥品工業

圖表一覽

目錄

The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs.

The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs.

Additionally, with the industry undergoing the period of "patent cliff", the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients.

A significant amount of research is being carried out currently to improve the level of potency of the already developed kinase inhibitors. Consequently, a relatively new approach has been indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers. However, still a lot of work needs to be done in this arena.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer kinase inhibitor drugs targets would be successfully identified for regulating tumor cell growth. Additionally, the innovations and dynamics in inhibitors would also allow for more efficient cytotoxic kinase inhibitor drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic targets.

"Global Cancer Kinase Inhibitors Market & Pipeline Insight" Report Highlight:

  • Classification & Mechanism of Kinase Inhibitors
  • Cancer Kinase Inhibitors Therapy Market Overview
  • Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
  • Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
  • Patent Analysis & Orphan Designation of Kinase Inhibitors
  • Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
  • Marketed Cancer Kinase Inhibitors: 35 Drugs

Table of Contents

1. Introduction to Kinase Inhibitors

  • 1.1 Cancer Growth Blockers
  • 1.2 Types of Cancer Growth Blockers
  • 1.3 Tyrosine Kinase Inhibitors

2. Kinase Inhibitors Classification

  • 2.1 Type I Kinase Inhibitors
  • 2.2 Type II Kinase Inhibitors
  • 2.3 Type III Kinase Inhibitors
  • 2.4 Type IV Kinase Inhibitors or Substrate Directed Inhibitors
  • 2.5 Covalent Inhibitors

3. Mechanisms of Kinase Inhibitors

  • 3.1 Biochemical Mechanism of Action of Tyrosine Kinase
  • 3.2 Oncogenic Activation of Tyrosine Kinase
    • 3.2.1 Activation by Mutation
    • 3.2.2 BCR-ABL and Human Leukemia
    • 3.2.3 TEL-ABL and Human Leukemia
    • 3.2.4 Autocrine-Paracrine Loops
    • 3.2.5 EGFR in Autocrine Paracrine Loops
    • 3.2.6 PDGFR in Autocrine Paracrine Loop
    • 3.2.7 Insulin like Growth Factor Receptors in Autocrine Growth Loop
  • 3.3 Tyrosine Kinases as Targets for Anticancer Agents

4. Need for Cancer Kinase Inhibitor Therapy

5. Cancer Kinase Inhibitors Therapy Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Cancer Kinase Inhibitors Pipeline Overview

6. Cancer Kinase Inhibitors Therapy Market Dynamics

  • 6.1 Favorable Parameters
  • 6.2 Growth Restraints

7. Cancer Kinase Inhibitors Therapy Market Future Outlook

8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country

  • 8.1 Phase: Unknown
  • 8.2 Phase: Research
  • 8.3 Phase: Preclinical
  • 8.4 Phase: Clinical
  • 8.5 Phase-I
  • 8.6 Phase-I/II
  • 8.7 Phase-II
  • 8.8 Phase-II/III
  • 8.9 Phase-III
  • 8.10 Preregistration
  • 8.11 Registered

9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country

10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline

  • 10.1 No Development Reported
  • 10.2 Discontinued
  • 10.3 Suspended

11. Competitive Landscape

  • 11.1 Amgen
  • 11.2 AstraZeneca
  • 11.3 AVEO Pharmaceuticals
  • 11.4 Bayer HealthCare Pharmaceuticals
  • 11.5 Boehringer Ingelheim
  • 11.6 Deciphera Pharmaceuticals
  • 11.7 Genentech
  • 11.8 GlaxoSmithKline
  • 11.9 Incyte Corporation
  • 11.10 Novartis
  • 11.11 Pfizer
  • 11.12 Takeda
  • Figure 2-1: Kinase Inhibitors Classification
  • Figure 3-1: Mechanisms of Constitutive Activation of Kinase Inhibitors
  • Figure 5-1: Global Market for Kinase Inhibitors (US$ Billion), 2013-2020
  • Figure 5-2: Global Market for Cancer Kinase Inhibitors (US$ Billion), 2013-2020
  • Figure 5-3: Regional Break-Up for Kinase Inhibitors Market (%), 2013 & 2020
  • Figure 5-4: Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-5: Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-6: No Development Reported in Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-7: No Development Reported in Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014
  • Figure 5-8: Discontinued Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-9: Discontinued Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014
  • Figure 5-10: Suspended Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-11: Suspended Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014
  • Table 1-1: Drugs Targeting Kinase Inhibitors
  • Table 2-1: Comparison Between Different Types of Kinase Inhibitors
Back to Top